In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Health Care Reform: For Biopharmas There Is Much To Like

Executive Summary

The passage of health reform was a momentous juncture for the health care industry, but is also just the beginning of years of policy development that amend or define the crucial details of the 2010 proposals. Analysts are still tallying the reform bill's final cost to biopharma companies; even so, the industry stands to gain more it gives up with the landmark legislation's passing.
Advertisement

Related Content

Physicians Have Bigger Stake In Patients' Total Care Under Medicare ACOs
A Look Back At 2010: In Search Of New Biopharma Models
Opening A Door To Biosimilars In The US
Best of The In Vivo Blog, April 2010
Health Care Reform and Business Development: 10 Reasons It Matters
A Two Pharma Horse Race In Follow-On Biologics
A Two Pharma Horse Race In Follow-On Biologics
Merck's Head-long Leap into Follow-On Biologics
Merck's Head-long Leap into Follow-On Biologics
FDA Hesitates on Biogenerics

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003474

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel